Raffi Asadorian Net Worth

The estimated Net Worth of Raffi Asadorian is at least $1.12 Миллион dollars as of 28 February 2019. Mr. Asadorian owns over 3,647 units of Acelrx Pharmaceuticals Inc stock worth over $106,981 and over the last 10 years he sold ACRX stock worth over $0. In addition, he makes $1,013,490 as Chief Financial Officer at Acelrx Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Asadorian ACRX stock SEC Form 4 insiders trading

Raffi has made over 7 trades of the Acelrx Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 3,647 units of ACRX stock worth $10,248 on 28 February 2019.

The largest trade he's ever made was buying 7,000 units of Acelrx Pharmaceuticals Inc stock on 11 September 2017 worth over $22,680. On average, Raffi trades about 1,273 units every 19 days since 2015. As of 28 February 2019 he still owns at least 124,397 units of Acelrx Pharmaceuticals Inc stock.

You can see the complete history of Mr. Asadorian stock trades at the bottom of the page.

Raffi Asadorian biography

Raffi M. Asadorian serves as Chief Financial Officer of the Company. He has served as our Chief Financial Officer since August 2017. Previously, Mr. Asadorian served as the Chief Financial Officer of Amyris, Inc., a publicly traded commercial-stage biotechnology company, from January 2015 to January 2017. Prior to Amyris, he served as the Chief Financial Officer of Unilabs, a private equity-owned medical diagnostics company, from August 2009 to October 2014. Mr. Asadorian started his career at PricewaterhouseCoopers (PwC) where he was a partner in its Transaction Services (M&A advisory) group. While at PwC, Mr. Asadorian advised Barr Pharmaceuticals, a publicly traded specialty pharmaceutical company, on its acquisition of PLIVA, a publicly traded pharmaceutical company, and, after its acquisition, Mr. Asadorian joined Barr as Senior Vice President and Chief Financial Officer of its PLIVA business from 2007 to 2009. In that role, Mr. Asadorian oversaw a global finance team and was responsible for Barr’s ex-US financial operations, until its acquisition by Teva Pharmaceuticals.

What is the salary of Raffi Asadorian?

As the Chief Financial Officer of Acelrx Pharmaceuticals Inc, the total compensation of Raffi Asadorian at Acelrx Pharmaceuticals Inc is $1,013,490. There are 2 executives at Acelrx Pharmaceuticals Inc getting paid more, with Vincent Angotti having the highest compensation of $2,125,050.

How old is Raffi Asadorian?

Raffi Asadorian is 50, he's been the Chief Financial Officer of Acelrx Pharmaceuticals Inc since 2017. There are 14 older and no younger executives at Acelrx Pharmaceuticals Inc. The oldest executive at Acelrx Pharmaceuticals Inc is Lawrence G. Hamel, 69, who is the Consultant.

What's Raffi Asadorian's mailing address?

Raffi's mailing address filed with the SEC is C/O ACELRX PHARMACEUTICALS, INC., 25821 INDUSTRIAL BLVD., SUITE 400, HAYWARD, CA, 94545.

Insiders trading at Acelrx Pharmaceuticals Inc

Over the last 14 years, insiders at Acelrx Pharmaceuticals Inc have traded over $25,363,406 worth of Acelrx Pharmaceuticals Inc stock and bought 5,245,025 units worth $26,783,172 . The most active insiders traders include Advisors Llcperceptive Life..., Advisors Llcedelman Josephp... и Mark Ajaeger Wilfred Ethree.... On average, Acelrx Pharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $109,939. The most recent stock trade was executed by Vincent J. Angotti on 13 December 2023, trading 10,000 units of ACRX stock currently worth $7,300.

What does Acelrx Pharmaceuticals Inc do?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Complete history of Mr. Asadorian stock trades at Acelrx Pharmaceuticals Inc и Amyris Inc

Acelrx Pharmaceuticals Inc executives and stock owners

Acelrx Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Vincent Angotti,
  Chief Executive Officer, Director
• Pamela Palmer,
  Co-Founder, Director, Chief Medical Officer
• Raffi Asadorian,
  Chief Financial Officer
• Vincent J. Angotti,
  CEO & Director
• Badri Dasu,
  Chief Engineering Officer
• Dr. Pamela Pierce Palmer,
  Co-Founder, Chief Medical Officer & Director
• Raffi Mark Asadorian,
  Chief Financial Officer
• Anil N. Dasu,
  Chief Engineering Officer
• Adrian Adams,
  Independent Chairman of the Board
• Mark Edwards,
  Independent Director
• Stephen Hoffman,
  Independent Director
• Mark Wan,
  Independent Director
• Richard Afable,
  Independent Director
• Howard Rosen,
  Independent Director
• Lawrence G. Hamel,
  Consultant
• C Steven Hoffman,
  Director
• Advisors Llcperceptive Life...,
  
• Lawrence G Hamel,
  Chief Development Officer
• Timothy E Morris,
  Chief Financial Officer
• Jane Wright Mitchell,
  Chief Legal Officer
• Advisors Llcedelman Josephp...,
  
• John G. Saia,
  General Counsel and Secretary
• Marina Bozilenko,
  Director
• David Chung,
  Chief Commercial Officer
• Venture Partners Qualified ...,
  
• Mark Ajaeger Wilfred Ethree...,
  
• James H Welch,
  Chief Financial Officer
• Thomas A Schreck,
  Director
• Guy P Nohra,
  Director
• Mark Ajaeger Wilfred Ethree...,
  
• Venture Partners Qualified ...,
  
• Richard King,
  President and CEO
• Arch Management Iii Llcwan ...,
  
• Arch Management Iv, L.L.C.T...,
  
• Iv, L.P.Nohra Guy Pjanney D...,
  
• Mark Ajaeger Wilfred Ethree...,
  
• Jill Marie Broadfoot,
  Director